Image de couverture de livre

Prevalence of cannabidiol use in persons with cystic fibrosis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Emma M. Tillman, Katherine A. Gallaway, Abi Colwell, Colleen Sakon, Cynthia D. Brown
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Pediatric Pulmonology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis
par: Rebecca S. Pettit, et autres
Publié: (2024)

Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer Risk
par: Tyler Shugg, et autres
Publié: (2025)

Time to be blunt: Substance use in cystic fibrosis
par: Sanaz Vaziri, et autres
Publié: (2024)

The foregut in cystic fibrosis
par: Christopher Vélez, et autres
Publié: (2024)

Nutrition and behavioral health in cystic fibrosis: Eating and body image
par: Emma R. Lyons, et autres
Publié: (2024)

Overnutrition in persons with cystic fibrosis on modulator therapy and the relationship to obstructive sleep apnea
par: Aesha M. Jobanputra, et autres
Publié: (2024)

The future of cystic fibrosis: A global perspective
par: Felix Ratjen
Publié: (2024)

Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
par: Kamyron Jordan, et autres
Publié: (2024)

Clinical evidence of pancreatic recovery in children with cystic fibrosis on ivacaftor
par: Sydney Walker, et autres
Publié: (2024)

Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis
par: CM. López Cárdenes, et autres
Publié: (2024)

Predicting weight gain in patients with cystic fibrosis on triple combination modulator
par: Kelly L. Stewart, et autres
Publié: (2024)

Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis
par: Anna M. Georgiopoulos, et autres
Publié: (2024)

Lung T1 MRI assessments in children with mild cystic fibrosis lung disease
par: Clement L. Ren, et autres
Publié: (2024)

Codevelopment of a model of care for adults living with cystic fibrosis‐related diabetes
par: Shanal Kumar, et autres
Publié: (2024)

The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis
par: Nicole Green, et autres
Publié: (2024)

Me, myself, and I: A systematic review of cystic fibrosis and self‐concept
par: Maggie Harrigan, et autres
Publié: (2024)

BMI increase during early childhood in boys with cystic fibrosis and early adrenarche
par: Gizem Tamer, et autres
Publié: (2024)

Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
par: Cameron J. McKinzie, et autres
Publié: (2024)

Comparison of particles in exhaled air and multiple breath washout for assessment of small airway function in children with cystic fibrosis
par: Annelies M. Zwitserloot, et autres
Publié: (2024)

Adding fuel to the fire: The growing case for global access to cystic fibrosis transmembrane conductance regulator modulator therapy
par: Brenda M. Morrow, et autres
Publié: (2024)

Evaluation of otorhinolaryngologic, audiologic, and genetic findings in children with cystic fibrosis: A tertiary care experience
par: Halime Nayır Büyükşahin, et autres
Publié: (2024)

Preferences and perspectives regarding telehealth exercise interventions for adults with cystic fibrosis: A qualitative study
par: Megan Poulsen, et autres
Publié: (2024)

The rebound effect: Reoccurrence of nasal polyps following discontinuation of a CFTR modulator in a patient with cystic fibrosis sinus disease
par: Brittany A. Wright, et autres
Publié: (2024)

Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis
par: Hiep Pham, et autres
Publié: (2024)

A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor
par: Nora Burdis, et autres
Publié: (2024)

Successful treatment of Stenotrophomonas maltophilia with ceftazidime‐avibactam and aztreonam in an individual with cystic fibrosis: A case report
par: Stephanie Duehlmeyer, et autres
Publié: (2024)

Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series
par: Shanal Kumar, et autres
Publié: (2024)

Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study
par: Nagehan Emiralioğlu, et autres
Publié: (2024)

Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome
par: Brian J. Carroll, et autres
Publié: (2024)

Nebulized granulocyte macrophage‐colony stimulating factor to stabilize lung function in nontuberculous mycobacteria pulmonary disease in cystic fibrosis
par: Colette Biro, et autres
Publié: (2024)

A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis
par: Sabrina J. Sherwood, et autres
Publié: (2024)

Implementation and outcomes of a quality improvement project to systematically assess the gross motor skills in school‐aged children with cystic fibrosis
par: Abby Good, et autres
Publié: (2024)

Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis
par: Emma M. Tillman, et autres
Publié: (2025)

“I eat chocolate milk for dinner because we just have nothing in our fridge”: The invisible burden and dire consequences of food insecurity for people with cystic fibrosis in the United States
par: Soumya J. Niranjan, et autres
Publié: (2024)

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
par: Valeria Daccò, et autres
Publié: (2024)

New York cystic fibrosis consortium newborn screening quality improvement: Development and implementation of a statewide consensus recommendations for management of infants with CFTR‐related metabolic syndrome
par: Saroj Choudhary, et autres
Publié: (2024)

Childhood exposure to cannabidiol and lung function: A pilot study
par: Nolan Younoszai, et autres
Publié: (2024)

Improving implementation and team communication by integrating a cystic fibrosis transition readiness (CF R.I.S.E.) program into electronic health records
par: Catherine Enochs, et autres
Publié: (2024)

A rare variant c.1802T>C (p. Ile601Thr) associated with severe phenotype among people with cystic fibrosis from south India, and potential genetic admixture in Réunion, France
par: Madhan Kumar, et autres
Publié: (2024)

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data
par: Don S. Urquhart, et autres
Publié: (2024)